ClinicalTrials.gg
CompletedNCT03019289Updated Nov 19, 2021Results posted

A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

A Phase 1 interventional study of pridopidine (90 mg) in Health Volunteers, Huntington Disease, sponsored by Prilenia. Completed at 1 site in Germany. Open to male participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Prilenia · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
25 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Huntington Disease with a site in Germany — 7 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Germany.

Enrollment
35th of 37
23 · median 95
Started
2017
with 3 others
Phase 1
5 of 44
1 open now
Registered
22nd of 44
by date
Lead sponsor
5 of 44
Prilenia

Among the 44 studies in Huntington Disease with a site in Germany, this one is the 35th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 5 in phase 1, and was the 22nd registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

7 of the 44 studies in Huntington Disease with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Huntington Disease with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted

03

Conditions studied

  • Health Volunteers, Huntington Disease

Browse trials for

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In general, good physical health as determined by medical history and psychiatric history, suicidality assessment \& physical examination
  • Men who are potentially fertile (not surgically [eg, vasectomy] or congenitally sterile
  • Patients with Huntington's disease (HD): diagnosis of HD and with an onset of HD after 18 years of age

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The subject has been previously exposed to ionizing radiation or radioactive substances as a result of clinical research or medical treatment in the past 10 years.
  • The subject has a counterindication to having an MRI
  • History of alcohol, narcotic, or any other substance dependence in the past 2 years
  • Additional Exclusion criteria to patients with Huntington's disease:
  • The patient has a severe motor impairment that might cause artifacts.
  • Patients with a known history of Long Syndrome or a first degree relative with this condition.
  • Treatment with any product within 6 weeks of screening or patients planning to participate in another clinical study assessing any investigational product during the study.

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    pridopidine

    Pridopidine (TV-7820) capsules

    Drug: pridopidine (90 mg)

Interventions

  • single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.

06

What researchers measure

Primary outcomes

  1. Sigma-1 Receptor Occupancy

    Receptor occupancy of pridopidine to Sigma-1 receptors (S1R) in the brain was assessed from Positron Emission Tomography (PET) imaging with (S)-(-)-\[18F\]fluspidine

    Time frame: 2 hours after oral administration of pridopidine

Secondary outcomes

  1. Maximum Plasma Concentration of Pridopidine

    Maximum plasma concentration of pridopidine based on noncompartmental analysis

    Time frame: PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.

  2. Time to Reach Maximum (Peak) Concentration (Tmax)

    Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.

    Time frame: PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.

Other outcomes

  1. Dopamine-2 Receptor Occupancy

    RO of D2 (Dopamine-2) at 2 hours after oral administration of pridopidine (90 mg dose level) was investigated in 4 healthy volunteers using \[18F\]fallypride

    Time frame: 2 h after pridopidine dosing

07

Results

Posted Nov 16, 2021

Participant flow

Healthy volunteers (HV) and patients with Huntington Disease (HD) were enrolled. The first participant was enrolled on 22 March 2017; the last subject completed the study on 09 February 2018.

Participant flow — Overall Study
MilestoneA: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HV
Started513211343
Completed313211342
Not completed200000001
Withdrew: Adverse event100000001
Withdrew: Other100000000

Outcome measures

PrimarySigma-1 Receptor Occupancy

Receptor occupancy of pridopidine to Sigma-1 receptors (S1R) in the brain was assessed from Positron Emission Tomography (PET) imaging with (S)-(-)-\[18F\]fluspidine

Time frame:
2 hours after oral administration of pridopidine
Reported as:
Mean · percentage of receptor occupancy
Sigma-1 Receptor Occupancy
percentage of receptor occupancyA: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HD
Sigma-1 Receptor Occupancy91.21 (88.82 to 95.67)87.19 (87.19 to 87.19)86.67 (84.06 to 89.24)77.96 (76.75 to 79.16)41.77 (41.77 to 41.77)17.55 (17.55 to 17.55)87.37 (80.36 to 93.23)
SecondaryMaximum Plasma Concentration of Pridopidine

Maximum plasma concentration of pridopidine based on noncompartmental analysis

Time frame:
PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of Pridopidine
ng/mLA: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + FPD; HV
Maximum Plasma Concentration of Pridopidine552 (496 to 614)307 (307 to 307)147 (117 to 184)25.9 (16.1 to 41.8)2.90 (2.90 to 2.90)1.33 (1.33 to 1.33)764 (666 to 877)452 (244 to 724)
SecondaryTime to Reach Maximum (Peak) Concentration (Tmax)

Multiple PK samples over 24 hours will be calculated for pridopidine and its metabolite TV-45065 in plasma using non-compartmental methods, when possible.

Time frame:
PK sampling 1 h before pridopidine dosing, and 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h after dosing.
Reported as:
Median · hours
Time to Reach Maximum (Peak) Concentration (Tmax)
hoursA: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HV
Time to Reach Maximum (Peak) Concentration (Tmax)1.97 (1.50 to 3.00)1.98 (1.98 to 1.98)1.00 (0.75 to 1.50)1.00 (0.75 to 1.50)1.98 (1.98 to 1.98)1.97 (1.97 to 1.97)1.00 (0.50 to 1.62)2.26 (1.00 to 5.02)
Other pre-specifiedDopamine-2 Receptor Occupancy

RO of D2 (Dopamine-2) at 2 hours after oral administration of pridopidine (90 mg dose level) was investigated in 4 healthy volunteers using \[18F\]fallypride

Time frame:
2 h after pridopidine dosing
Reported as:
Mean · percent volume/volume
Dopamine-2 Receptor Occupancy
percent volume/volumeB: Cohort 4: P90 + FPD; HV
Dopamine-2 Receptor Occupancy3.34 ± 2.05

Adverse events

Collected over From signing of the informed consent through to 7 days after the last administration of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: Cohort 1: P90 + (S)-(-)-FPD; HV0/5 (0%)0/5 (0%)2/5 (40%)
A: Cohort 2: P45 + (S)-(-)-FPD; HV0/1 (0%)0/1 (0%)1/1 (100%)
A: Cohort 2: P22.5 + (S)-(-)-FPD; HV0/3 (0%)0/3 (0%)1/3 (33.3%)
A: Cohort 3: P5 + (S)-(-)-FPD; HV0/2 (0%)0/2 (0%)0/2 (0%)
A: Cohort 7: P1 + (S)-(-)-FPD; HV0/1 (0%)0/1 (0%)0/1 (0%)
A: Cohort 7: P0.5 + (S)-(-)-FPD; HV0/1 (0%)0/1 (0%)0/1 (0%)
A: Cohort 6; P90 + (S)-(-)-FPD; HD0/3 (0%)0/3 (0%)1/3 (33.3%)
B: Cohort 4: P90 + Fallypride; HV0/4 (0%)0/4 (0%)1/4 (25%)
Cohort 0: (S)-(-)-FPD, HV0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventA: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HV
Catheter site hematomaGeneral disorders0/50/10/30/20/10/10/30/43/3
Haemoglobin decreasedInvestigations2/51/10/30/20/10/10/30/40/3
VomitingGastrointestinal disorders0/50/10/30/20/10/10/31/41/3
Catheter site painGeneral disorders0/50/10/30/20/10/10/30/41/3
Catheter site paraesthisiaGeneral disorders0/50/10/30/20/10/10/30/41/3
Vessel puncture site haematomaGeneral disorders0/50/10/30/20/10/10/30/41/3
ConjunctivitisInfections and infestations0/50/10/30/20/10/11/30/40/3
NasopharyngitisInfections and infestations0/50/10/30/20/10/11/30/40/3
Skin abrasionInjury, poisoning and procedural complications0/50/11/30/20/10/10/30/40/3
Sports injuryInjury, poisoning and procedural complications0/50/11/30/20/10/10/30/40/3

Baseline characteristics

All subjects/patients enrolled

Age, Continuous
Age, Continuous(years)A: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HVTotal
Median28.0 (27 to 30)26.0 (26 to 26)25.0 (25 to 28)27.5 (27 to 28)30 (30 to 30)25.0 (25 to 25)40.0 (32 to 58)28.0 (25 to 35)29.0 (25 to 30)28 (25 to 58)
Sex: Female, Male
Sex: Female, Male(Participants)A: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HVTotal
Female51321134323
Male0000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)A: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HVTotal
White51321134222
Black/African American0000000011
Region of Enrollment
Region of Enrollment(participants)A: Cohort 1: P90 + (S)-(-)-FPD; HVA: Cohort 2: P45 + (S)-(-)-FPD; HVA: Cohort 2: P22.5 + (S)-(-)-FPD; HVA: Cohort 3: P5 + (S)-(-)-FPD; HVA: Cohort 7: P1 + (S)-(-)-FPD; HVA: Cohort 7: P0.5 + (S)-(-)-FPD; HVA: Cohort 6; P90 + (S)-(-)-FPD; HDB: Cohort 4: P90 + Fallypride; HVCohort 0: (S)-(-)-FPD, HVTotal
Germany51321134323
08

Study locations

1 site
  • Teva Investigational Site 32648
    Leipzig, 04103, Germany
09

References and documents

Publications

  • Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek F, Rullmann M, Sattler B, Patt M, Gerhards T, Strauss M, Kluge A, Brust P, Savola JM, Gordon MF, Geva M, Hesse S, Barthel H, Hayden MR, Sabri O. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1103-1115. doi: 10.1007/s00259-020-05030-3. Epub 2020 Sep 29. PubMed 32995944 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Feb 2018, 9 months.

Results were first posted in Nov 2021, 3 years 9 months after primary completion.

Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 12, 2017
StartActual
Apr 19, 2017
Primary completionActual
Feb 9, 2018
CompletionActual
Feb 9, 2018
Results first posted
Nov 16, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03019289
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Jan 12, 2017
Start date
Apr 19, 2017
Primary completion
Feb 9, 2018
Completion
Feb 9, 2018
Results posted
Nov 16, 2021
Last update
Nov 19, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Pharmaceuticals USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion